N UCLEAR medicine is one the most important fields to inspect and treat tumors by radiation or by introducing labeled radiopharmaceuticals, which are in the spot of our interest. In this study, the authors investigated the possibility of using mebeverine as a solid tumor marker. Mebeverine was labeled with Technetium ( 99m Tc-Meb) reaching a radiochemical yield (RCY) of 97% via a reduction reaction using SnCl 2 . The tracer showed a high stability in the serum for 12 hours which is essential to avoid any undesired accumulations in the non-target organs. Its bioevaluation in normal and induced tumored mice was performed to identify the capability of the use of the tracer for the diagnosis of solid tumors. The uptake by the tumor was 14.2% after 30 min of injection and increased to 18.5%, viewing a decline after 3 hours, this could be attributed to that washout to the tumored muscle extravasation. Tumored /Non-Tumored (T/ NT) ratio was applied, the ratio reached 3.14 which shows the selectivity of 99m Tc-Meb to the solid tumor induced in the right thigh.

No abstract

No abstract

Ulcerative colitis (UC) is a chronic, regressive natural disease. The use of conventional diagnostic procedures such as magnetic resonance imaging, ultrasonography, and X-rays during the dormant and early stages of the disease does not aid in diagnosing the disease. As a result, a novel design, such as labelled compounds, were used to image ulcerative colitis disease. In this study, olsalazine was labeled with [ 125/131 I] and the labelling parameters were adjusted to obtain a high radiochemical yield (98.5%). In addition, the olsalazine radiotracer gave 96.0% purity in rate serum for up to twelve hours before it started to degrade at twenty-four hours, and it was stable also, in saline for up to twentyfour hours. Molecular docking was used to assess a complex's affinity for its biological target, and the PPAR receptor. The biological assessment was also performed in mice models of both standard and ulcerative colitis. The results demonstrated that [ 125/131 I] iodoolsalazine had a high uptake of 79.5% (ID/g) at 120 minutes post-injection and is still high to 77% at 24 hours. So, the labelled compound, [ 125/131 I] iodoolsalazine, could be considered a new potential selective radiotracer for preclinical diagnostic research of ulcerative colitis.

No abstract